Mark Chin

Track

Insider profile

Currently holds a position at Iterum Therapeutics PLC

Performance

Overall performance
2.8
Performance over holding periods
4.2
30 days 90 days 120 days
Average return 1% 8.2% 15.1%
Success rate 41% 68% 82%
Transactions
4 50% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return 37%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance

Positions

Position Company Period
Independent Director Iterum Therapeutics PLC May 1, 2017 -
Mark Chin's trades of Pyxis Oncology Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Sale
Price
425.00
Quantity 47,986 -13.3%
Value US$1,040,243
Transaction date
Purchase
Price
187.15
Quantity 56,583 +17.6%
Value US$1,176,086
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2022-04-25 2022-04-21
S Sale
47,986 -13.3%
425.00
US$1,040,243 		47,986 -13.3% 425.00 US$1,040,243
2021-10-15 2021-10-13
B Purchase
56,583 +17.6%
187.15
US$1,176,086 		56,583 +17.6% 187.15 US$1,176,086
2020-03-16 2020-03-16
B Purchase
76,207 +31.0%
89.35
US$1,393,828 		76,207 +31.0% 89.35 US$1,393,828
2019-12-10 2019-12-06
S Sale
47,752 -1.7%
19.15
US$914,222 		47,752 -1.7% 19.15 US$914,222
2019-02-14 2019-02-12
B Purchase
428,571 +17.4%
14.00
US$5,999,994 		428,571 +17.4% 14.00 US$5,999,994